What if Your Clinical Genome Test Could Do More?
More Informed Results with Multimodal Data Analysis
Baylor Genetics’ Multimodal Data Analysis brings together different genomic modalities for even more answers to guide patient care and outcomes.
Genome Analysis
Enables the detection of clinically relevant genetic variants across the genome
Complex Structural Variant (SV) Analysis
Clarify large or complex genomic rearrangements related to a wide spectrum of rare genetic diseases
Short Tandem Repeat (STR) Analysis
Detect expansions in 58 STRs to identify neurological, neuromuscular, and other disorders
Methylation Analysis of FMR1
Detect FMR1 gene methylation status in Fragile X-associated conditions
RNA Sequencing
(RNA-Seq) Analysis
Supplemental targeted RNA analysis to support clearer result interpretation patient-specific variants
Mitochondrial DNA
(mtDNA) Analysis
Full mtDNA genome sequencing for disorders with neurological and multisystem involvement
Uniparental Disomy
(UPD) Analysis
Detection of disorders where both chromosome copies originate from one parent
Metabolomic Analysis
Identify and clarify findings associated with heritable metabolic conditions
Ordered as a separate test (Global MAPS®) and reported separately from WGS
Our updated Whole Genome Sequencing now offers improved detection for patients with:
-
Unresolved clinical features
-
Progressive neurologic symptoms
-
Fragile X-related clinical presentations
Dive deeper into how complementary technologies like Optical Genome Mapping and Long‑Read Sequencing expand the clinical impact of Whole Genome Sequencing to detect complex structural variants, methylation, and repeat‑based findings that traditional approaches may miss.
Connect With Us For Updates
Note: When appropriate, Baylor Genetics may supplement Whole Genome Sequencing (WGS) with RNA Sequencing (RNA-Seq) for variant classification and/or Optical Genome Mapping (OGM) for complex structural variant analysis. A final report will be issued prior to initiating RNA‑Seq or OGM, with any resulting updates provided through an addended report. Additional specimens may be requested as needed. Complex SV analysis (with OGM) as well as STR and methylation analysis using long-read sequencing are not approved in New York State. Comparator samples are excluded from RNA-Seq, complex SV (with OGM), and STR analyses.